

DAFTAR PUSTAKA

1. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. *The Oncologist* 2001;6:15-23.
2. Kwok C. Management of side effects from chemotherapy. The Hongkong anti cancer society 2010. Available from URL: <https://www.google.com/#q=Management+of+Side+Effects+from+Chemotherapy+Dr.+Carol+Kwok>. Accessed November 11,2014.
3. Hassan BAR. Role of cancer and chemotherapy in the incidence of thrombocytopenia. *Pharmaceut Anal Acta* 2013;4:1-2
4. Hassan BAR, Yussof ZBM, Hassali MA, Othman SB. Treatment patterns and outcome in management of Solid cancer patients suffering from thrombocytopenia in Penang Hospital. *Asian Pacific J of Cancer Prev* 2011;12:2841-45.
5. Blay BGY, Cesne AL, Mermet C, Ravaud A, Chevreau C, Sebban C, *et al.* A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. *American Society of Hematology* 1998;92:405-10.
6. Wormann B. Clinical indications for thrombopoietin and thrombopoietin receptor agonist. *Transfus Med Hematol* 2013;40:319-25.
7. Mc Cullough J. Current issues with platelet transfusion in patients with cancer. *Semin Hematol* 2000;37:3-10.
8. Linda S, Scott B, Charles G, Hamblin L, Kurtin D, Rivera E, *et al.* Cost of Chemotherapy induced thrombocytopenia among patients with lymphoma or solid tumors. *American cancer society* 2003;97:1541-50.
9. Wendling F, Cohen-Solal K, Villeval JL, Debili N, Vainchenker W. Mpl ligand or thrombopoietin: biological activities. *Biotherapy* 1998;10:269-77.
10. Kuter DJ. New thrombopoietic growth factor. *Blood J* 2007;11:4607-15.
11. Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. *Cancer research* 1995;55:3509-12.
12. Lijima K, Sugita K, Inukai T, Goi. K, Tezuka T, Uno K, *et al.* Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation of philadelphia chromosome. *Leukemia* 2000;14:1598-1605.

13. Pavithran K. Thrombopoietin. Departemen of Haematology Medical College Hospital 2009. Available from URL:
<http://www.priory.com/med/thrombo.htm>. Accessed November 11,2014.
14. Folman CC, deJong SCM, Haas MD, Borne VD. Analysis of the kinetics of thrombopoietin uptake during platelet transfusion. Division of internal medicine and dept of haematology academic medical centre Amsterdam the Netherland 2009:59-65.
15. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonist. *Int J Hematol* 2013;98:10-23.
16. Ikeda Y, Miyakawa Y. Development of thrombopoietin receptor agonist for clinical use. *Journal of Thrombosis and haemostasis* 2009;7:239-44.
17. Roberto S, Bosworth J, Rhodes E, Muriel S, Shannon, Fenella W. Thrombopoietic agents. *Blood reviews* 2010;24:179-90.
18. Saur SJ, Sangkhae V, Geddis AE, Khaushansky K, Hitchcock IS. Ubiquitination and degradation of the thrombopoietin receptor c-MPL. *Blood* 2010;115:1254-63.
19. Sekhon S, Roy V. Thrombocytopenia in adults: approach to evaluation and management. *Southern Medical Journal* 2006;99:491-8.
20. Elkurt MA, Kaya E, Berber I, Koroglu M, Kuku I. Thrombocytopenia in adults:review article. *J. Hematol* 2012;1:44-53.
21. Stasi R. How to approach thrombocytopenia. *Haematology* 2012:191-7.
22. Korshed A, Abbas A, Kawy SA, Kholoussi N, Elghoroury, Salam HA. Role of thrombopoietin in megakaryopoiesis and thrombopoiesis with relation to platelet ultrastruktur. *J. Med Sci* 2007;7:179-186.
23. Wolber EM, Jelkmann W. Thrombopoietin: The novel hepatic hormone. *News Physiol Sci* 2002;17:6-10
24. Vigon I, Mornon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S et al: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. *Proc Natl Acad Sci U S A* 1992, 89:5640-44.
25. Methia N, Louache F, Vainchenker W, Wendling F: Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopenesis. *Blood* 1993,82:1395-1401.
26. Fiedler K, Brunner C. Mechanism controlling hematopoiesis. *Hematology Science and practice* 2012:1-45.

27. John P.G, John F, George M.R, Frixos P, Bertil G, Daniel A et al. Means. Wintrobe's clinical hematology 12th ed. 2012:1289-90.
28. Warr MR, Pietras EM, Passegue E. Mechanism controlling hematopoietic stem cell function during normal hematopoiesis and hematological malignancies. Jhons wiley & sons 2011:681-701
29. Pinheiro D, Sunkel C. Mechanism of cell cycle control. Fevereiro 2012:1-16.
30. Bhel C, Ziegler C. Cell cycle: the life cycle of a cell. Molecular mechanism and implications for disease 2014: 9-19.
31. Morgan G. Chemotherapy and the cll cycle. Clinical 2007:27-30
32. Goldwein JW, Vachani C. Chemotherapy:the basics. Cancer resources for patient and healthcare professional 2014. Available from URL: <http://www.oncolink.org/treatment/article.cfm?c=142&id=319>. Accessed November 14,2014
33. Robinson A, Oijen MV. Replication, transcription and translation:mechanism insight from single-molecule biochemical studies. Nature reviews 2013;11:303-15
34. Taanman JW. The mitichondrial genome:structure, transcription, translation and replication. Biochimica et biophysica 2003:103-23.
35. Tanner M. Regulation of thrombopoietin receptor expression and function. Experimentelle hamatologie German 2004:7-13
36. Christina R, Coers J. A Truncated isoform of c-MPL. The Journal of Biological chemistry 2004;279.36397-404.
37. Wendling F, Vainchenker W. Thrombopoietin and it's receptor the protooncogen c-MPL. Rapid science publisher 1995:331-8.
38. Broudy VC, Khaushansky K. Thrombopoietin the c-MPL ligand, is a major regulator of platelet production. Journal of Leukocyte Biology 1995;57:719-25.
39. Gurney Al, Carver MK, de Sauvage FJ, Moore MW. Thrombocytopenia in c-MPL defficient mice. Science 1994;265:1445-47.
40. Skoda RC. The control of normal and aberrant megakaryopoiesis by thrombopoietin and it's receptor c-MPL 2006. Available from URL: www.cloetta-stiftung.ch/wp.../05/Skoda Ref.pdf. Accessed November 14,2014
41. Aglietta M, Caravelli D. Thrombocytopenia risk in oncology patients. Journal of platelets 2010;1:9-12.

42. Hittron, Anna, Steinke, Doug, Sutphin, Stephanie, *et al.* Incidence and risk factor of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. *Journal of oncology pharmacy practice* 2011;17:312-19.
43. Ninos M, Jefferies LC, Cogle CR, Kerr WG. The thrombopoietin receptor c-MPL is a selective surface marker for human hemaopoietic stem cells. *Journal of translation medicine* 2006;4:1-18.
44. Kuefer MU, Wang WC, Dead DR, Williams. Thrombopoietin levels in young patients in related to megakaryocyte frequency and platelet count. *J patients hematol oncol* 1998;20:36-43.
45. Nagasawa T, Hagesawa Y, Shimizn. Serum thrombopoietin level in mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. *Br J Hematol* 1998;101:242-46.
46. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. *Salemba Medika* 2013:36-80.
47. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. *Cancer network* 2015:2-17
48. Blay JY, Cesce L, Mermet C, Mougard C, Ravaud C, Chevreau C. A Risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. *Blood Journal* 1998;92: 1-7.
49. Henk VDB, Paulussen M, Teuff GL, Judson I, Genderblom H, Dirksen U. Impact of gender on efficacy and acute toxicity of alkylating agent based chemotherapy in ewing sarcoma. *European J of Cancer* 2015;51:2453-64,
50. Kaminski A, Joseph D, Elsaleh H, Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. *Australian radiology* 2007;51:283-88.
51. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, *et al.* sex and age related chemotherapy toxicity in patients non metastatic osteosarcoma. *Journal of chemotherapy* 2009;21:205-10.
52. Sabine OP, Vera RZ. Sex and gender aspects in clinical medicine. *Spinger* 2012:165-68.
53. Vianello F, Vettore S, Tezza F, Toni LD, Sambado L, Treleani M, *et al.* serum thrombopoietin and cMPL expression in thrombocytopenia of different etiologies. *Hematology reports* 2014;6:7-11
54. Mitchel SC. Dose reduction and delay: limitation of myelosuppressive chemotherapy. *cancer network* 2005 available in: <http://www.cancernetwork.com/review-article/dose-reductions-and-delays-limitations-myelosuppressive-chemotherapy>. Accessed November 16, 2014